Phase 4 Kidney Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Your child is between 2 months old and 17 years old and has cancer
- Your child is likely to develop a fever with a very low white blood cell count (which can happen during cancer treatment) at some point during the study
- Parents must be willing to give written permission for their child to take part, and teenagers aged 14 and older must also give their own written agreement
- Your child has a fever (temperature of 38°C or higher lasting at least one hour, or a single reading of 38.5°C or higher) along with a dangerously low level of infection-fighting white blood cells, or is expected to reach that low level within the next 24 hours due to ongoing chemotherapy
- If your child had a previous episode in this study that was treated with antibiotics, at least 2 weeks must have passed since that antibiotic treatment ended
Who may not be able to join:
- Your child's low white blood cell count is not caused by cancer or chemotherapy
- The family or patient does not wish to take part
- The parents, or patients older than 11 years, do not speak French
- Your child does not experience a fever with very low white blood cells during the study period (this would be confirmed after joining)
- Your child has very severe kidney problems (confirm with trial site)
- Your child is pregnant
- It is not possible to get a blood medication level result back within 72 hours of taking the sample — for example, if admission happens just before a public holiday when the lab is closed
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Pierre-Alex Crisinel, Centre Hospitalier Universitaire Vaudois
Phone: +41(0)795563598
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Achievement of antibiotic concentration targets in the intervention group (1i) vs control groupe (1c)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.